Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mylan Pharmaceuticals Inc.

https://www.mylan.com

Latest From Mylan Pharmaceuticals Inc.

Teva Quits PhRMA As Financial, Policy Challenges Loom For The Brand/Generic Hybrid Giant

With a leadership position in the US generics association and a new CEO focused on how to reallocate resources, Teva leaves the brand trade association after a review of the ‘effectiveness and value of engagements.’

Business Strategies Legislation

Rezafungin Review Highlights US FDA’s ‘Flexible Development' Approach For Antimicrobials

Cidara developed the antifungal for candidemia/invasive candidiasis pursuant to the FDA’s 2017 ‘Unmet Need guidance,’ which provides an avenue for approval with a 'limited use' indication based on a streamlined development program. Some of the guidance recommendations also have been leveraged under the LPAD pathway.

Infectious Diseases Review Pathway

At The Edge Of The Cliff: Five Blockbuster Drugs Set To Lose US Patent Exclusivity In 2023

With the advent of 2023, comes the start of the industry’s next patent cliff, with five products that reached billions in sales at their peak set to lose US patent exclusivity during the year. Scrip takes a look into how the affected big pharma firms are preparing for anticipated market erosion and which generic and biosimilar companies are positioned to benefit the most.

Scrip Perspectives Generic Drugs

Dark Territory: Lifting The Veil On GPOs And PBMs

Based on a new report by the Wharton School, this article tackles criticisms against the intermediaries that connect buyers and sellers, the GPO and PBM. It also analyzes the existential threats facing these intermediaries such as 'safe harbors', threats of disintermediation, and the consolidation of suppliers.

Market Access Safety
See All

Company Information

  • Industry
  • Pharmaceuticals
UsernamePublicRestriction

Register